Pulmonary complications of inflammatory myopathy

Rheumatic Disease Clinics of North America

Volumn 41, Issue 2, 2015, Pages 249-262

  Miller, Shelly A ^a   Glassberg, Marilyn K ^a   Ascherman, Dana P ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibodies; Dermatomyositis; Inflammatory myopathy; Interstitial lung disease (ILD); Polymyositis

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE;

ASPIRATION PNEUMONIA; CONGESTIVE HEART FAILURE; CYCLOPHOSPHAMIDE INDUCED PNEUMONITIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; METHOTREXATE INDUCED PNEUMONITIS; MYOSITIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; REVIEW; SPONTANEOUS PNEUMOMEDIASTINUM; COMPLICATION; IMMUNOLOGY; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL;

HUMANS; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; MYOSITIS;

EID: 84926201938     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.12.006     Document Type: Review

References (69)

1. Hallowell R., Ascherman D., Danoff S. Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med 2014, 35:239-248.
2. Mills E., Mathews W. Interstitial pneumonitis in dermatomyositis. JAm Med Assoc 1956, 160(17):1467-1470.
3. Mimori T., Nakashima R., Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 2012, 14(3):264-274.
4. Chen I.J., Jan We Y.J., Lin C., et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009, 28(6):639-646.
5. Marie I., Hatron P.Y., Dominique S., et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011, 63(11):3439-3447.
6. Marie I., Ménard J., Hachulla E., et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 2011, 41(1):48-60.
7. Tobin R., Pope C., Pellegrini C., et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158(6):1804-1808.
8. Green H., Paul M., Vidal L., et al. Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007, (18). [review], CD005590.
9. Enomoto T., Azuma A., Matsumoto A., et al. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia. Intern Med 2008, 47(1):15-20.
10. Mori S., Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) 2012, 51(12):2120-2130.
11. Marie I., Hachulla E., Chérin P., et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005, 53(2):155-165.
12. Hervier B., Meyer A., Dieval C., et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J 2013, 42(5):1271-1282.
13. Denbow C., Lie J., Tancredi R., et al. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum 1979, 22(10):1088-1092.
14. Selva-O'Callaghan A., Sanchez-Sitjes L., Munoz-Gall X., et al. Respiratory failure due to muscle weakness in inflammatory myopathies: maintenance therapy with home mechanical ventilation. Rheumatology (Oxford) 2000, 39(8):914-916.
15. Le Goff B., Chérin P., Cantagrel A., et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009, 61(1):108-118.
16. Imokawa S., Colby T., Leslie K., et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000, 15(2):373.
17. Malik S., Myers J., DeRemee R., et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996, 154(6):1851-1856.
18. Savage R.L., Highton J., Boyd I.W., et al. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006, 36(3):162-169.
19. Hadjinicolaou A.V., Nisar M.K., Bhagat S., et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review. Rheumatology (Oxford) 2011, 50(12):2297-2305.
20. Won Huh J., Soon Kim D., Keun Lee C., et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 2007, 101(8):1761-1769.
21. Koreeda Y., Higashimoto I., Yamamoto M., et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010, 49(5):361-369.
22. Marie I., Josse S., Hatron P.Y., et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013, 65(5):800-808.
23. Love L., Leff R., Fraser D., et al. Anew approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991, 70(6):360-374.
24. Hamaguchi Y., Fujimoto M., Matsushita T., et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 2013, 8(4):e60442.
25. Hervier B., Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep 2013, 15(8):349.
26. Brouwer R., Hengstman G.J., Egberts W.V., et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60(2):116-123.
27. Mimori T., Imura Y., Nakashima R., et al. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007, 19(6):523-529.
28. Solomon J., Swigris J., Brown K. Myositis-related interstitial lung disease and antisynthetase syndrome. JBras Pneumol 2011, 37(1):100-109.
29. Marie I., Hachulla E., Chérin P., et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002, 47(6):614-622.
30. Richards T., Eggbeen A., Gibson K., et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009, 60(7):2183-2192.
31. Mileti L., Strek M., Niewold T., et al. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. JClin Rheumatol 2009, 15(5):254-255.
32. Fischer A., Swigris J.J., du Bois, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med 2009, 103(11):1719-1724.
33. Yousem S., Schneider F., Bi D., et al. The pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome. Hum Pathol 2014, 45(6):1199-1204.
34. Kalluri M., Sahn S., Oddis C., et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009, 135(6):1550-1556.
35. Schneider F., Yousem S., Bi D., et al. Pulmonary pathologic manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy. JClin Pathol 2014, 67(8):678-683.
36. Kunimasa K., Arita M., Nakazawa T., et al. The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis. Intern Med 2012, 51(24):3405-3410.
37. Betteridge Z., Gunawardena H., North J., et al. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007, 46(6):1005-1008.
38. Cao H., Pan M., Kang Y., et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 2012, 64(10):1602-1610.
39. Sarkar K., Weinberg C., Oddis V., et al. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined subgroups. Arthritis Rheum 2005, 52(8):2433-2438.
40. Muro Y., Suguira K., Hoshino K., et al. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther 2009, 13(6):R214. 10.1186/ar3547.
41. Tomohiro K., Fujikawa L., Horai Y., et al. The diagnostic utility of anti-melanoma differentiation-association gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 2012, 51:1278-1284.
42. Fiorentino D., Chung L., Zwerner J., et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. JAm Acad Dermatol 2011, 65(1):25-34.
43. Tanizawa K., Handa T., Nakashima R., et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 2013, 107(5):745-752.
44. Fujimoto M., Hamaguchi Y., Kaji K., et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012, 64(2):513-522.
45. Hengstman G., van Engelen B., van Venrooij W. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004, 16(6):692-699.
46. Kao A.H., Lacomis D., Lucas M., et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004, 50(1):209-215.
47. Ghirardello A., Zampieri S., Iaccarino L., et al. Anti-Mi-2 antibodies. Autoimmunity 2005, 38(1):79-83.
48. Kawasumi H., Gono T., Kawaguchi Y., et al. IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositis. Biomed Res Int 2014, 2014:815245.
49. Gono T., Kawaguchi Y., Hara M., et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010, 49(7):1354-1360.
50. Kubo M., Ihn H., Kikuchi K., et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology 2000, 39(6):632-636.
51. Fathi M., Barbasso Helmers S., Lundberg I. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. JIntern Med 2012, 271(6):589-597.
52. Douglas H., Tazelaar T., Hartman R., et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001, 164:1182-1185.
53. Lynch D., Travis W., Muller N., et al. Idiopathic interstitial pneumonias: CT features. Radiology 2005, 236:10-21.
54. Bouchardy L., Kuhlman J., Ball W.J., et al. CT findings in bronchiolitis obliterans organizing pneumonia (BOOP) with radiographic, clinical, and histologic correlation. JComput Assist Tomogr 1993, 17:352-357.
55. Ikezoe J., Johkoh T., Kohno N., et al. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis. JThorac Imaging 1996, 8(4):250-259.
56. Tillie-Leblond I., Wislez M., Valeyre D., et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008, 63(1):53-59.
57. Sauty A., Rochat T., Schoch O., et al. Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997, 10(12):2907-2912.
58. Tazelaar H., Viggiano R., Pickersgill J., et al. Interstitial lung disease in polymyositis and dermatomyositis, clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990, 141(3):727-733.
59. Yoshifuji H., Fujii T., Kobayashi S., et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006, 39(3):233-241.
60. Swigris J., Olson A., Fischer A., et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006, 130(1):30-36.
61. Morganroth P.A., Kreider M.E., Werth V.P. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010, 62(10):1496-1501.
62. Yamasaki H., Yamada H., Yamasaki M., et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007, 46(1):124-130.
63. Takada K., Nagasaka K., Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005, 38(5):383-392.
64. Kameda H., Nagasawa H., Ogawa H., et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. JClin Rheumatol 2005, 32(9):1719-1726.
65. Kotani T., Takeuchi T., Makino S., et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 2011, 30(8):1021-1028.
66. Kurita T., Yasuda S., Oba K., et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford) 2015, 54(1):39-44.
67. Wilkes M.R., Sereika S.M., Fertig N., et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005, 52(8):2439-2446.
68. Sem M., Molberg O., Lund M., et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009, 48(8):968-971.
69. Viguier M., Fouere S., de la Salmoniere P., et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) 2003, 82:82-86.